Sci Transl Med:美研发出急性髓细胞白血病新药

2018-04-12 周舟 新华社

美国《科学·转化医学》杂志11日发表的研究显示,一种小蛋白质药物有望用于治疗急性髓细胞白血病,目前已在美国进入临床试验阶段。

美国《科学·转化医学》杂志11日发表的研究显示,一种小蛋白质药物有望用于治疗急性髓细胞白血病,目前已在美国进入临床试验阶段。

此前已有研究显示,如果MDMX和MDM2两种基因过度表达,就会抑制抗癌基因p53的活性,从而导致某些癌症。但此前医学界研究的抗癌药物还局限于MDM2抑制剂。

美国爱因斯坦医学院等机构的研究人员研发了一种可以同时抑制MDMX和MDM2的新药,充分激活p53,使其发挥抗癌功效。这种新药属于订书肽。订书肽的螺旋结构更稳定,可以避免药物在到达靶点前被酶降解。

动物实验显示,这种新药可将移植了人类白血病细胞的小鼠的中位生存期从50天延长到150天。约40%的小鼠甚至被该药治愈,超过一年没有发病。

研究人员表示,新药不仅有望用于治疗急性髓细胞白血病,还有望用于治疗其他与p53相关的癌症。

原始出处:

Luis A. Carvaja, Daniela Ben Neriah, Adrien Seneca, et.al. Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia. Science Translational Medicine  11 Apr 2018

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1656989, encodeId=24741656989e9, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Nov 09 02:16:00 CST 2018, time=2018-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822164, encodeId=4cce1822164b6, content=<a href='/topic/show?id=b8611021308a' target=_blank style='color:#2F92EE;'>#髓细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102130, encryptionId=b8611021308a, topicName=髓细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Fri Jan 04 03:16:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067336, encodeId=3414206e3362a, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Jan 25 04:16:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300134, encodeId=ffec1300134a1, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Apr 14 13:16:00 CST 2018, time=2018-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468182, encodeId=e8011468182b6, content=<a href='/topic/show?id=71c810212946' target=_blank style='color:#2F92EE;'>#髓细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102129, encryptionId=71c810212946, topicName=髓细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69e46898758, createdName=chengjn, createdTime=Sat Apr 14 13:16:00 CST 2018, time=2018-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608743, encodeId=10141608e433e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Apr 14 13:16:00 CST 2018, time=2018-04-14, status=1, ipAttribution=)]
    2018-11-09 bsmagic9140
  2. [GetPortalCommentsPageByObjectIdResponse(id=1656989, encodeId=24741656989e9, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Nov 09 02:16:00 CST 2018, time=2018-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822164, encodeId=4cce1822164b6, content=<a href='/topic/show?id=b8611021308a' target=_blank style='color:#2F92EE;'>#髓细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102130, encryptionId=b8611021308a, topicName=髓细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Fri Jan 04 03:16:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067336, encodeId=3414206e3362a, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Jan 25 04:16:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300134, encodeId=ffec1300134a1, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Apr 14 13:16:00 CST 2018, time=2018-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468182, encodeId=e8011468182b6, content=<a href='/topic/show?id=71c810212946' target=_blank style='color:#2F92EE;'>#髓细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102129, encryptionId=71c810212946, topicName=髓细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69e46898758, createdName=chengjn, createdTime=Sat Apr 14 13:16:00 CST 2018, time=2018-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608743, encodeId=10141608e433e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Apr 14 13:16:00 CST 2018, time=2018-04-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1656989, encodeId=24741656989e9, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Nov 09 02:16:00 CST 2018, time=2018-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822164, encodeId=4cce1822164b6, content=<a href='/topic/show?id=b8611021308a' target=_blank style='color:#2F92EE;'>#髓细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102130, encryptionId=b8611021308a, topicName=髓细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Fri Jan 04 03:16:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067336, encodeId=3414206e3362a, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Jan 25 04:16:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300134, encodeId=ffec1300134a1, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Apr 14 13:16:00 CST 2018, time=2018-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468182, encodeId=e8011468182b6, content=<a href='/topic/show?id=71c810212946' target=_blank style='color:#2F92EE;'>#髓细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102129, encryptionId=71c810212946, topicName=髓细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69e46898758, createdName=chengjn, createdTime=Sat Apr 14 13:16:00 CST 2018, time=2018-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608743, encodeId=10141608e433e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Apr 14 13:16:00 CST 2018, time=2018-04-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1656989, encodeId=24741656989e9, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Nov 09 02:16:00 CST 2018, time=2018-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822164, encodeId=4cce1822164b6, content=<a href='/topic/show?id=b8611021308a' target=_blank style='color:#2F92EE;'>#髓细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102130, encryptionId=b8611021308a, topicName=髓细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Fri Jan 04 03:16:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067336, encodeId=3414206e3362a, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Jan 25 04:16:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300134, encodeId=ffec1300134a1, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Apr 14 13:16:00 CST 2018, time=2018-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468182, encodeId=e8011468182b6, content=<a href='/topic/show?id=71c810212946' target=_blank style='color:#2F92EE;'>#髓细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102129, encryptionId=71c810212946, topicName=髓细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69e46898758, createdName=chengjn, createdTime=Sat Apr 14 13:16:00 CST 2018, time=2018-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608743, encodeId=10141608e433e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Apr 14 13:16:00 CST 2018, time=2018-04-14, status=1, ipAttribution=)]
    2018-04-14 lqvr
  5. [GetPortalCommentsPageByObjectIdResponse(id=1656989, encodeId=24741656989e9, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Nov 09 02:16:00 CST 2018, time=2018-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822164, encodeId=4cce1822164b6, content=<a href='/topic/show?id=b8611021308a' target=_blank style='color:#2F92EE;'>#髓细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102130, encryptionId=b8611021308a, topicName=髓细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Fri Jan 04 03:16:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067336, encodeId=3414206e3362a, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Jan 25 04:16:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300134, encodeId=ffec1300134a1, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Apr 14 13:16:00 CST 2018, time=2018-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468182, encodeId=e8011468182b6, content=<a href='/topic/show?id=71c810212946' target=_blank style='color:#2F92EE;'>#髓细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102129, encryptionId=71c810212946, topicName=髓细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69e46898758, createdName=chengjn, createdTime=Sat Apr 14 13:16:00 CST 2018, time=2018-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608743, encodeId=10141608e433e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Apr 14 13:16:00 CST 2018, time=2018-04-14, status=1, ipAttribution=)]
    2018-04-14 chengjn
  6. [GetPortalCommentsPageByObjectIdResponse(id=1656989, encodeId=24741656989e9, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Nov 09 02:16:00 CST 2018, time=2018-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822164, encodeId=4cce1822164b6, content=<a href='/topic/show?id=b8611021308a' target=_blank style='color:#2F92EE;'>#髓细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102130, encryptionId=b8611021308a, topicName=髓细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Fri Jan 04 03:16:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067336, encodeId=3414206e3362a, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Jan 25 04:16:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300134, encodeId=ffec1300134a1, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Apr 14 13:16:00 CST 2018, time=2018-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468182, encodeId=e8011468182b6, content=<a href='/topic/show?id=71c810212946' target=_blank style='color:#2F92EE;'>#髓细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102129, encryptionId=71c810212946, topicName=髓细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69e46898758, createdName=chengjn, createdTime=Sat Apr 14 13:16:00 CST 2018, time=2018-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608743, encodeId=10141608e433e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Apr 14 13:16:00 CST 2018, time=2018-04-14, status=1, ipAttribution=)]

相关资讯

P53基因重排/突变的白血病非淋巴结套细胞淋巴瘤对利妥昔单抗/伊布替尼组合疗法高度敏感

白血病型非淋巴结套细胞淋巴瘤(L-NN-MCL)是一种相对罕见的套细胞淋巴瘤亚型,通常被认为是无痛性的。尽管对L-NN-MCL的深入认识能够避免过度治疗,但部分患者具有更激进的L-NN-MCL形式并呈现出症状性疾病和/或血细胞减少症。在此,研究人员为我们展示了两例需要进一步治疗的侵袭性L-NN-MCL案例。两例患者的细胞遗传学和DNA测序研究显示17号染色体或P53基因异常,两例患者均接受利妥昔单

中国儿童急性淋巴细胞白血病长期生存率接近国际发达国家水平

中新网上海4月8日电 国家儿童医学中心--上海儿童医学中心8日披露,该院牵头开展的ALL(小儿急性淋巴细胞白血病)多中心临床研究表明,儿童急淋白血病5年以上长期生存率较10年前上升近10%,总体已近90%,接近国际发达地区水平。在当日举行的“2018年白血病精准医学国际工作会议”上,国家卫健委儿童白血病专家委员会正式组建,将汇聚血液肿瘤领域顶尖专家共同商讨癌症诊疗“卡脖”因素,共商白血病规范化诊

Leukemia:上海交大蒙国宇团队揭示癌蛋白DUX4/IGH在白血病中的发病机制

急性淋巴细胞白血病(acute lymphoblastic leukemia,ALL)为起源于淋巴干祖细胞克隆增殖的血液系统恶性疾病,全美在20岁前人群发病率约为30例/百万人,且高发率出现在3~5岁,是儿童中最常见的白血病类型。儿童ALL依据细胞表面与胞质表达的髓系标记可分为B淋巴干祖细胞克隆(占比约85%)与T淋巴干祖细胞克隆(占比约15%),因此,急性B淋巴细胞白血病的临床诊断与治愈引起了研

中国蒽环类药物在白血病治疗中的临床应用专家共识

蒽环类药物是一类对白血病具有高效作用的抗癌药物,主要有柔红霉素(daunorubicn,DNR)、去甲氧柔红霉素(idarubicin,IDA)、米托蒽醌(mitoxantrone,MIT)等。

病例:Ph阳性髓性白血病BCR-ABL融合基因两种少见型报道

慢性髓性白血病(CML)的分子生物学特征为BCR-ABL融合基因阳性。研究发现,BCR-ABL融合基因根据BCR的断裂位点不同,主要分为三种类型:①M型(major),包括b2a2(e13a2)和b3a2(e14a2),编码相对分子质量210×103的BCR-ABL融合蛋白;②m型(minor)ela2,编码相对分子质量190×103的BCR-ABL融合蛋白;③u型e19a2,编码相对分子质量23

Antimicrob Agents Ch:万古霉素预防治疗小儿急性骨髓性白血病有何不良反应?

2018年2月,发表于《Antimicrob Agents Chemother》上的一项研究,考察了小儿急性骨髓性白血病(AML)治疗中,基于静脉万古霉素的预防治疗的不良反应。